Amgen Inc. stock (US0311621009): Q1 earnings beat with $5.15 EPS

Amgen Inc. reported Q1 2026 earnings on April 30, beating estimates with $5.15 EPS and $8.62 billion revenue, up 5.8% year-over-year. Shares traded at $331.70 on May 11.

Amgen Inc. released its Q1 2026 earnings on April 30, 2026, posting adjusted EPS of $5.15, surpassing analyst consensus of $4.77 by $0.38. Quarterly revenue climbed 5.8% year-over-year to $8.62 billion, slightly above the $8.58 billion expected, according to MarketBeat as of May 2026. The stock traded at $331.70 on May 11, 2026, on Nasdaq.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Amgen Inc.
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: US, Europe, global
• Key revenue drivers: Oncology, inflammation, rare diseases
• Home exchange/listing venue: Nasdaq (AMGN)
• Trading currency: USD

Amgen Inc.: core business model

Amgen Inc. develops and markets human therapeutics targeting serious illnesses in oncology, inflammation, bone, cardiovascular, and rare diseases. The company pioneered biologic medicines, with key products like Enbrel, Prolia, and Repatha driving revenue. Its model focuses on innovation through R&D, manufacturing scale, and global partnerships, serving US investors via Nasdaq listing.

Amgen's pipeline emphasizes next-generation biologics and biosimilars, supported by a robust manufacturing network including facilities in Puerto Rico and the US mainland. This infrastructure ensures supply chain reliability for high-demand therapies.

Main revenue and product drivers for Amgen Inc.

Oncology remains Amgen's largest segment, with products like Kyprotec and Xgeva contributing significantly. In Q1 2026, overall revenue reached $8.62 billion, up 5.8% from the prior year, per the April 30 release cited on MarketBeat as of May 2026. Inflammation drugs such as Otezla and Tezspire also bolster growth.

Rare disease and cardiovascular portfolios, including Evenity and Repatha, provide diversified streams. Amgen generated $14.37 EPS over the last four quarters ending Q1 2026.

Industry trends and competitive position

The biotech sector faces patent cliffs but benefits from obesity and oncology demand. Amgen invests in manufacturing, announcing a $300 million expansion in Puerto Rico in early May 2026 to enhance biologics capacity, according to Simply Wall St as of May 2026. This positions Amgen competitively against peers like Eli Lilly and Regeneron.

Why Amgen Inc. matters for US investors

Listed on Nasdaq, Amgen offers US investors exposure to biotech leadership with strong US market revenue. Its products address prevalent health issues like cancer and osteoporosis, aligning with aging demographics and healthcare spending trends in the US economy.

Conclusion

Amgen Inc. demonstrated solid Q1 2026 results with EPS and revenue beats, alongside manufacturing investments signaling long-term capacity growth. Shares held steady at $331.70 amid broader biotech dynamics. Investors track upcoming catalysts like pipeline updates for sustained performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.